Solution- Pharmacy's video: Pharmacokinetic Properties of Calcium Channel Blockers GPAT NIPER Pharmacist Examination

Download the "Solution Pharmacy" Mobile App to Get All Uploaded Notes, Model Question Papers, Answer Papers, Online Tests and other GPAT Materials - https://play.google.com/store/apps/details?id=co.bolton.nqilv Book Review Video - https://youtu.be/icz2MGUmXSA Purchase from Amazon = https://amzn.to/3S0K68h Table of Content https://www.thieme.in/image/catalog/TOC/Bhandari%20TOC.pdf Sample Chapter of this book https://www.thieme.in/image/catalog/Sample%20Chapter/Bhandari%20sample%20chapter.pdf Calcium channel blockers (CCBs) are a class of medications commonly used to treat various cardiovascular conditions, such as hypertension (high blood pressure), angina (chest pain), and certain arrhythmias (irregular heart rhythms). These drugs exert their therapeutic effects by selectively blocking the influx of calcium ions into cardiac and smooth muscle cells, thereby reducing muscle contraction and vasodilation of blood vessels. Pharmacokinetic properties play a crucial role in determining the drug's onset, duration of action, and elimination from the body. CCBs exhibit diverse pharmacokinetic profiles due to variations in their chemical structures and drug formulations. Some key pharmacokinetic properties of CCBs include: 1. Absorption: The route of administration significantly influences the absorption of CCBs. Oral formulations are most common, and absorption rates vary among different agents. For instance, immediate-release formulations are rapidly absorbed, while extended-release formulations provide a sustained release of the drug over a more extended period. 2. Distribution: CCBs have moderate to high protein-binding capabilities, particularly to plasma proteins like albumin. This binding influences the distribution of the drug throughout the body and may affect drug interactions with other highly protein-bound drugs. 3. Metabolism: The liver primarily metabolizes CCBs, particularly through the cytochrome P450 (CYP) enzyme system. The metabolism rate varies among different CCBs, leading to variations in their half-lives and duration of action. 4. Half-life: The half-life of CCBs can vary from a few hours to several days, depending on the specific agent. Short-acting CCBs, like nifedipine, have relatively short half-lives, necessitating multiple daily doses. In contrast, long-acting CCBs, such as amlodipine and felodipine, have longer half-lives, enabling once-daily dosing. 5. Elimination: After metabolism, CCB metabolites are predominantly excreted via the kidneys, although some undergo biliary excretion. Renal impairment may require dose adjustments to avoid potential drug accumulation and adverse effects. 6. Interactions: CCBs have the potential to interact with other medications that are metabolized through the same CYP pathways, leading to drug interactions that may either potentiate or reduce the effects of the co-administered drugs. Get in touch with the solution by just clicking the following links- Facebook Group- https://www.facebook.com/groups/solutionpharamcy Mobile App - https://play.google.com/store/apps/details?id=co.bolton.nqilv New Channel (Pharmacy Dictionary) https://www.youtube.com/channel/UCt6OXVV_2oxf5DD0Mad6e9A E-Mail for official and other work - solutionpharmacy@gmail.com